TWD 56.6
(-4.87%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -246.6 Million TWD | -195.47% |
2022 | -80.66 Million TWD | 41.31% |
2021 | -137.43 Million TWD | -130.91% |
2020 | -59.51 Million TWD | 38.58% |
2019 | -96.9 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -192.82 Million TWD | 34.05% |
2024 Q1 | -292.37 Million TWD | -18.56% |
2023 Q3 | -247.94 Million TWD | -1.7% |
2023 Q2 | -243.79 Million TWD | -779.49% |
2023 Q4 | -246.6 Million TWD | 0.54% |
2023 Q1 | -27.72 Million TWD | 65.63% |
2022 Q4 | -80.66 Million TWD | 0.0% |
2022 FY | -80.66 Million TWD | 41.31% |
2021 FY | -137.43 Million TWD | -130.91% |
2020 FY | -59.51 Million TWD | 38.58% |
2019 FY | -96.9 Million TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Apex Biotechnology Corp. | -201.21 Million TWD | -22.559% |
Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | 128.328% |
Panion & Bf Biotech Inc. | 193.2 Million TWD | 227.639% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | 126.248% |
GenMont Biotech Incorporation | 2.71 Million TWD | 9193.215% |
Abnova (Taiwan) Corporation | -415.8 Million TWD | 40.692% |
Adimmune Corporation | 685.12 Million TWD | 135.994% |
Tanvex BioPharma, Inc. | 1.35 Billion TWD | 118.253% |
Polaris Group | -2.41 Billion TWD | 89.805% |
UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | 553.074% |
PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | 5152.407% |